Nova Mentis Launches Autism Microbiome Study in the United States
Nova Mentis Launches Autism Microbiome Study in the United States News provided by Share this article Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: " Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes." "NOVA's mission is to discover more precise ways to diagnose and treat autism spectrum disorder (ASD), an unmet medical need," stated Julia V. ...
Source: newswire.ca